As the cultural conversation around testosterone deficiency grows, more telehealth platforms are entering the market. Hims, a company known for its direct-to-consumer services, recently launched a testosterone replacement therapy service. The company offers two types of injectable treatments and an oral pill option, which patients can receive after taking an at-home capillary blood test. Peter Stahl, a urologist and senior vice president of men's health at Hims, aims to test as many people as possible to address the underdiagnosed and misunderstood condition. Hims, which started as a platform for erectile dysfunction medications, has expanded into women's health and grown to serve 2.9 million customers since its launch in 2017. Offering TRT is a new phase for the company, and they see it as a way to address a complex condition. Testosterone levels have become a point of contention, with some politicians and military officials promoting mandatory testing. Hims' survey of 2,000 American men indicates that while more men are willing to discuss testosterone treatment, stigma persists. The company's services require synchronous care, with patients having to video chat with a clinician before receiving a prescription and for ongoing monitoring. Hims emphasizes the importance of monitoring and the potential risks of TRT, such as infertility. For those interested in testing their testosterone levels, Hims offers a convenient and reliable option. Other recommendations include considering lifestyle changes, such as exercise and diet, to support healthy testosterone levels. It's important to consult with a healthcare provider to determine the best course of action for managing low T.
